TG Therapeutics Stock News

Within the last quarter, TG Therapeutics (NASDAQ:TGTX) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 1 1 Last

TG Therapeutics (TGTX) closed at $13.20 in the latest trading session, marking a +0.61% move from the prior day.

TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

TG Therapeutics (TGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

TG Therapeutics (TGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Presentation scheduled for Monday, January 9, 2023 at 9:45 AM PT Presentation scheduled for Monday, January 9, 2023 at 9:45 AM PT

Presentation scheduled for Monday, January 9, 2023 at 9:45 AM PT Presentation scheduled for Monday, January 9, 2023 at 9:45 AM PT

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. Here is a look at the most

Gainers Gorilla Technology Group Inc. (NASDAQ: GRRR) shares rose 162% to $21.30 in pre-market trading after jumping over 35% on Friday. Gorilla Technology recently said it is entering the MENA regio

TG Therapeutics, Inc. is set to launch Briumvi with an experienced in-house team. There are several factors conducive to launch success. Nevertheless, uncertainty remains.

Two new Breakout Stocks for Week 1 with better than 10% short-term upside potential and two Dow 30 Picks. Average cumulative returns for 2022 reached +142.69% YTD. The streak of weekly picks gaining o

The company scored a giant victory on the regulatory front.

The company scored a giant victory on the regulatory front.

Within the last quarter, TG Therapeutics (NASDAQ:TGTX) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 0 1 1 Last